Congenital Hyperinsulinism

• FDA approval · 2015-09-18
  FDA Approved: PROGLYCEM — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

  FDA approved a supplemental application for PROGLYCEM (diazoxide) from Teva Pharmaceuticals USA, Inc.

• CLINICAL_TRIALS trial_result · 2014-04-09
  Clinical Trial Update: Towards Individualized Surgery in Non-focal Congenital Hyperinsulinism

  A completed clinical trial exploring individualized surgical approaches for non-focal congenital hyperinsulinism.

• CLINICAL_TRIALS trial_result · 2013-12-19
  Clinical Trial Update: Sandostatine® LP and Hyperinsulinism [Phase 2]

  A Phase 2 clinical trial evaluating Sandostatine LP for congenital hyperinsulinism has completed.

• FDA approval · 2013-11-21
  FDA Approved: PROGLYCEM — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

  The FDA approved a supplemental NDA for PROGLYCEM (diazoxide) from Teva Pharmaceuticals USA, expanding or updating its labeling.

• CLINICAL_TRIALS research · 2013-03-27
  Clinical Trial Update: Long Term Glucose Metabolism in Conservatively Treated Patients With Congenital Hyperinsulinism

  A clinical trial update focusing on long-term glucose metabolism in conservatively treated patients with congenital hyperinsulinism; the cur…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2008-12-17
  FDA Approved: PROGLYCEM — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

  FDA approved a supplemental application for PROGLYCEM (diazoxide) from Teva Pharmaceuticals USA, Inc., indicating an update to the product's…